Overexpression of CC3/TIP30 is associated with HER-2/neu status in breast cancer

Abstract

Our findings suggest a potential link between the expression of CC3/TIP30 gene and the HER-2/neu oncogene-mediated signal pathway.These findings could not have been predicted from previous experimental studies, and suggest that CC3/TIP30 may play a complex role in breast cancer.

High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker

“…In addition to these studies demonstrating the role of HER2/neu in gynecological cancers, Zhang et al . reported that overproduction of HTATIP2/TIP30 is associated with HER2/neu status in breast cancer [10]. All of these studies support our findings that HTATIP2/TIP30 has a potential role in ovarian cancer, and that HER2/neu expression may be related to increased HTATIP2/TIP30 levels.…”

“…In addition to these studies demonstrating the role of HER2/neu in gynecological cancers, Zhang et al . reported that overexpression of human HIV-1 TAT interactive protein 2 (HTATIP2/TIP30) is associated with HER2/neu status in breast cancer [10]. …”

TIP30/CC3 expression in breast carcinoma: relation to metastasis, clinicopathologic parameters, and P53 expression

“…Recently, TIP30 was found to interact with coactivator independent of AF-2 function and negatively regulate estrogen receptor (ER) a-mediated c-myc expression [8]. Studies on clinical samples showed that TIP30/CC3 expression was significantly associated with positive HER-2/neu status at both mRNA and protein levels [9]. The expression profile of TIP30/CC3 in clinical specimens of cancers, especially in breast cancer, has not been well characterized.…”

Proteomics and Mass Spectrometry for Cancer Biomarker Discovery

“…To date, several studies have utilized RPMA in the analysis of cancer signaling pathway alterations with clinical prostate (Paweletz et al 2001; Grubb et al 2003; Herrmann et al 2003), ovarian (Wulfkuhle et al 2003; Sheehan et al 2005), colorectal (Belluco et al 2005), breast cancer (Zhang DH et al 2005a, b; Cowherd et al 2004, Wulfkuhle et al 2002; Kersting et al 2004) and lymphoma (Zha et al 2004; Gulmann et al 2005) specimens using RPMA. In these studies, pro-survival, pro-mitogenic, and cell-cycle regulatory proteins, including phospho-Akt, PI3K, ERK, MAPK, PKCα, p38, STAT1, GSK3-β, cytochrome c oxidase, c-erbB2, and c-erbB1, phospho-PTEN, EGFR, have been studied.…”